Sun Pharma settles generic Protonix® litigation

Sun Pharmaceutical Industries Ltd. 17/B, Mahal Industrial Estate, Mahakali Caves Road, Andheri (East), Mumbai 400 093 India Tel.: (91-22) 6645 5645 Fax.: (91-22) 6645 5685 Registered Office : SPARC, Tandalja, Vadodara – 390 020. India Corporate Office : Acme Plaza, Andheri – Kurla Road, Andheri (East), Mumbai – 400 059. India FOR IMMEDIATE RELEASE Sun Pharma settles generic Protonix® litigation Mumbai, June 12, 2013: Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) today announced that it togeth er with its subsidiaries, have settled an ongoing litigation pending in the United States District Court, District of New Jersey (“Court”) regarding Sun Pharma subsidiary’s generic pantoprazole. Under the terms of the litigation settlement between Sun Phar ma, and Wyeth, (now a division of Pfizer Inc.,) and Altana Pharma AG, (now known as Takeda GmbH) the parties have dismissed all their claims. Sun Pharma will pay a lump-sum US $550 million as a part of this settlement. In 2005, Wyeth and Altana had filed a patent infringement suit against Sun Pharma after Sun Pharma filed its abbreviated new drug application for pantoprazole. Sun Ph arma launched its generic pantoprazole in the US on January 30, 2008. In April 2010, a jury had determined that Altana’s patent is not invalid. On June 3, 2013, the Court began a jury trial to assess the amount of past da mages that Sun Pharma owed for infringing Altana’s now expired patent. This settlement now culminates the ongoing litigation. Sun Pharma can continue to sell its generic pantoprazole in the U.S. About Sun Pharmaceutical Industries Ltd. Established in 1983, listed since 1994 and headquartered in Indi a, Sun Pharmaceutical Indust ries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) is an intern ational, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulat ions as branded generics as well as generics in India, US and several other markets across the world. In India, the compan y is a leader in niche therapy areas of psychiatry, neurology, cardiology, nephrology, gastro enterology, orthopedics and ophthalmology. The company has strong skills in product development, process chemistry, and manufacturing of complex A P I , a s w e l l a s d o s a g e f o r ms. More information about the company can be found at www.sunpharma.com. Contacts Nimish Desai Mira Desai Tel +91 22 6645 5645, Xtn 717 Tel +91 22 6645 5645, Xtn 606 Tel Direct +91 22 66455717 Tel Direct +91 22 66455606 Mobile +91 98203 30182 Mobile +91 98219 23797 E mail [email protected] E mail [email protected]

The release as fetched from its publisher. sunpharma.com ↗